Drugs / NNC0113-6856
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06069895 | Oct 2023 → Apr 2025 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05521256 | Aug 2022 → Mar 2023 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0113-6856 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06069895 ↗ |
| Route | Intravenous | “Participants will receive NN0113-6856 orally or intravenously.” NCT05521256 ↗ |
| Route | Oral | “Participants will receive NN0113-6856 orally or intravenously.” NCT05521256 ↗ |